List of Bristol-Myers Squibb patents

Patents where

Current Assignee

Name

Bristol-Myers Squibb

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10072082 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10072082 was granted and assigned to Bristol-Myers Squibb on September, 2018 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10072082	September 11, 2018
‌ US Patent 6946079 Centrifugal filtration method for separating fibrin monomer from blood	Patent 6946079 was granted and assigned to Bristol-Myers Squibb on September, 2005 by the United States Patent and Trademark Office.		Bristol-Myers Squibb	United States Patent and Trademark Office	6946079	September 20, 2005
‌ US Patent 7332303 Product quality enhancement in mammalian cell culture processes for protein production	Patent 7332303 was granted and assigned to Bristol-Myers Squibb on February, 2008 by the United States Patent and Trademark Office.		Bristol-Myers Squibb	United States Patent and Trademark Office	7332303	February 19, 2008
‌ US Patent 10584170 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10584170 was granted and assigned to Bristol-Myers Squibb on March, 2020 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10584170	March 10, 2020
‌ US Patent 10138299 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10138299 was granted and assigned to Bristol-Myers Squibb on November, 2018 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10138299	November 27, 2018
‌ US Patent 10266596 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10266596 was granted and assigned to Bristol-Myers Squibb on April, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10266596	April 23, 2019
‌ US Patent 10266595 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10266595 was granted and assigned to Bristol-Myers Squibb on April, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10266595	April 23, 2019
‌ US Patent 10323093 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10323093 was granted and assigned to Bristol-Myers Squibb on June, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10323093	June 18, 2019
‌ US Patent 10266594 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10266594 was granted and assigned to Bristol-Myers Squibb on April, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10266594	April 23, 2019
‌ US Patent 10316091 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10316091 was granted and assigned to Bristol-Myers Squibb on June, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10316091	June 11, 2019
‌ US Patent 10323092 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10323092 was granted and assigned to Bristol-Myers Squibb on June, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10323092	June 18, 2019
‌ US Patent 11345752 Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof	Patent 11345752 was granted and assigned to Bristol-Myers Squibb on May, 2022 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	11345752	May 31, 2022
‌ US Patent 10577423 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10577423 was granted and assigned to Bristol-Myers Squibb on March, 2020 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10577423	March 3, 2020
‌ US Patent 10100129 Antibodies against CD73 and uses thereof	Patent 10100129 was granted and assigned to Bristol-Myers Squibb on October, 2018 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10100129	October 16, 2018
‌ US Patent RE39680 Substituted heterocycle fused gamma-carbolines	Patent RE39680 was granted and assigned to Bristol-Myers Squibb on June, 2007 by the United States Patent and Trademark Office.		Bristol-Myers Squibb	United States Patent and Trademark Office	RE39680	June 5, 2007
‌ US Patent 7189829 Baboon TAFI polypeptides	Patent 7189829 was granted and assigned to Bristol-Myers Squibb on March, 2007 by the United States Patent and Trademark Office.		Bristol-Myers Squibb	United States Patent and Trademark Office	7189829	March 13, 2007
‌ US Patent 10251945 Anti-ICOS agonist antibodies and uses thereof	Patent 10251945 was granted and assigned to Bristol-Myers Squibb on April, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10251945	April 9, 2019
‌ US Patent 10308714 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10308714 was granted and assigned to Bristol-Myers Squibb on June, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10308714	June 4, 2019
‌ US Patent 10316090 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10316090 was granted and assigned to Bristol-Myers Squibb on June, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10316090	June 11, 2019
‌ US Patent RE39679 Substituted heterocycle fused gamma-carbolines	Patent RE39679 was granted and assigned to Bristol-Myers Squibb on June, 2007 by the United States Patent and Trademark Office.		Bristol-Myers Squibb	United States Patent and Trademark Office	RE39679	June 5, 2007
‌ US Patent 10266591 Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof	Patent 10266591 was granted and assigned to Bristol-Myers Squibb on April, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10266591	April 23, 2019
‌ US Patent 10377824 Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof	Patent 10377824 was granted and assigned to Bristol-Myers Squibb on August, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10377824	August 13, 2019
‌ US Patent 7138643 Method and apparatus for separating ions of metallic elements in aqueous solution	Patent 7138643 was granted and assigned to Bristol-Myers Squibb on November, 2006 by the United States Patent and Trademark Office.		Bristol-Myers Squibb	United States Patent and Trademark Office	7138643	November 21, 2006
‌ US Patent 9605080 Antibodies against CD73	Patent 9605080 was granted and assigned to Bristol-Myers Squibb on March, 2017 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	9605080	March 28, 2017
‌ US Patent 8399623 Human antibodies that bind mesothelin, and uses thereof	Patent 8399623 was granted and assigned to Bristol-Myers Squibb on March, 2013 by the United States Patent and Trademark Office.		Bristol-Myers Squibb	United States Patent and Trademark Office	8399623	March 19, 2013

...

Results per page:

2,200 results

0 selected

2,200 results

0 selected